Nature Cancer May issue cover

Series on Cancer Immunotherapy

Check out our Series on the evolving palette of cancer immunotherapies, comprising Reviews, Perspectives and opinion pieces on the latest advances and challenges in clinical translation.


  • We're looking for Associate/Senior Editors to join our team in our New York, Berlin or Shanghai offices. Other locations in the US, Europe and China where Springer Nature has an office will also be considered on a case by case basis. Application deadline June 5th.

  • Image of a painter's palette, Nature Cancer's June issue cover.

    Nature Cancer's Series on Cancer immunotherapy comprises commissioned Reviews, Perspectives and opinion pieces on the latest advances in the evolving palette of immunotherapies, the challenges in clinical translation of promising preclinical discoveries and their application to a wider patient population.

  • Nature Cancer pictorial

    View webcasts hosted by Nature Cancer editors, in which expert cancer researchers and clinicians discuss the most exciting advances and biggest challenges in their fields. Past events can be accessed on demand for free by registering your attendee details.

  • Nature Cancer Series Cover - image of medications in ingestible and injectable form.

    Join us in New York City for our 3rd Nature Conference with MSKCC on "The Tumour Landscape: Translating Mechanism to Therapy". This meeting will focus on how to translate recent technological, biological, translational and clinical advances of the tumor ecosystem to the clinic. October 29, 2023 – November 1, 2023. Register now!

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.


    • Therapeutic products containing CD8+ and CD4+ T cells expressing CARs are effective at inducing remission in patients with cancer. How CD4+ CAR T cells contribute to the anti-tumor response has not been well established. A study uses syngeneic models and in vivo imaging to glean mechanistic insights into how CD4+ T cells target tumors.

      • M. Eric Kohler
      • Terry J. Fry
      News & Views
    • Rebbeck, Huang and colleagues discuss recent insights into health inequities related to clinical next-generation sequencing for precision oncology, the contributing factors as well as recommendations for resolution looking ahead.

      • Ritika Dutta
      • Mounica Vallurupalli
      • Timothy R. Rebbeck
    • Antigen presentation is fundamental to anti-tumor immunity, but our understanding of the physiological and molecular inputs to the process in different contexts remains limited. Two new studies explore the contribution of cell-intrinsic proteolytic mechanisms and cell-extrinsic hot and cold tumor microenvironments in shaping the antigenic landscape in lung cancer.

      • Paul A. Stewart
      • Alex M. Jaeger
      News & Views
    • An antisense RNA, NQO1-AS, binds and stabilizes its sense strand, upregulating the redox enzyme NQO1 in metastatic breast cancer cells. Overexpression of NQO1 facilitates lung colonization by suppressing oxidative stress and ferroptosis, and cancer cells dependent on this pathway can be targeted by a combined therapy that induces ferroptosis while simultaneously inhibiting NQO1.

      Research Briefing
    • Glioblastomas have limited treatment options and dire prognoses. A study now shows that GAP43-mediated transfer of functional mitochondria from astrocytes to glioblastoma cells leads to metabolism, signaling and epigenome remodeling that favor tumor growth, thus highlighting GAP43 inhibition as a promising therapeutic strategy for glioblastoma.

      • Martina Semenzato
      • Luca Scorrano
      News & Views
  • Charles Rudin completed his MD, PhD, medical and oncology training at the University of Chicago, where he joined the department of medicine faculty in 1998. He directed the lung, esophageal and head and neck cancer program at Johns Hopkins University from 2003 to 2013, while also serving as associate cancer center director for clinical research. He joined Memorial Sloan Kettering Cancer Center in 2013 as chief of thoracic oncology, co-director of the Druckenmiller Center for Lung Cancer Research, and the Sylvia Hassenfeld Chair in Lung Cancer Research.

    • Charles M. Rudin
    Turning Points
  • Mark A. Dawson obtained his medical degree from the University of Melbourne, followed by a PhD from the University in Cambridge. From 2010 to 2014, he was a Wellcome-Beit fellow at the University of Cambridge, and thereafter he joined the Peter MacCallum Cancer Centre as a consultant hematologist and group leader of the cancer epigenetics laboratory. In 2016, he was appointed co-program head of the Cancer Biology and Therapeutics Program, and in 2019 as associate director for research.

    • Mark A. Dawson
    Turning Points
  • Recent progress in melanoma treatment is based on research that poorly represents global population diversity, with little focus on relevant subtypes for non-European and admixed populations. However, there is an opportunity to change this and contribute to a more accurate understanding of melanoma worldwide.

    • Patricia A. Possik
    World View
  • Elaine R. Mardis earned her PhD at the University of Oklahoma, in the laboratory of Bruce Roe. After postgraduate work at Bio-Rad Laboratories in California, she joined the Washington University School of Medicine faculty in 1993. In 2016, she moved to Nationwide Children’s Hospital and is a Professor of Pediatrics at The Ohio State University. She was elected to the US National Academy of Medicine in 2019.

    • Elaine R. Mardis
    Turning Points
Image of different types of therapies, including pills and injectables, taken from the March 2021 issue cover of Nature Cancer.

Series on Cancer Therapy

Cancer therapy has advanced significantly in recent years, however, cancer remains a major health problem that requires further discovery and innovation to improve outcomes and quality of life for patients.


Nature Careers


  • Faculty Positions at SUSTech Department of Biomedical Engineering

    The Department of Biomedical Engineering (BME) , Southern University of Science and Technology (SUSTech), seeks outstanding applicants for full-tim...


    Department of Biomedical Engineering, SUSTech

  • Postdoctoral Fellows/Research scientists

    We are seeking for highly motivated postdoctoral fellows to join in Dr. Thanh Hoang?s lab in the University of Michigan. Our research encompasses a...

    United States, Ann Arbor, University of Michigan

    University of Michigan

  • Postdoctoral Research Fellow


    Boston, Massachusetts (US)

    Boston Children's Hospital (BCH)

  • Specialist in Genetic Trials and Precision Medicine

    The position We are looking for a highly qualified and innovative Specialist in Genetics Trials and Precision Medicine, to implement cutting-edge h...

    Oxford, Oxfordshire

    Novo Nordisk

  • Post doctor (2 years) within carbon burial in Arctic lakes

    The Department of Ecology and Environmental Science is offering a postdoctoral scholarship within a project on carbon burial in Arctic lakes.

    Umeå, Sweden

    Umeå University